Abstract
Background
Extraskeletal osteosarcoma (ESOS) is an extremely rare soft tissue sarcoma. Their prognosis remains poor. Our purposes were to identify the effective chemotherapeutic regimen for ESOS.
Methods
We retrospectively reviewed 16 patients with ESOS treated at the Osaka University Orthopaedic Oncology Group between 1992 and 2012. We extracted the clinical data on patients. Kaplan–Meier method and the log-rank test were used for survival analyses.
Results
Median age of the patients was 61.5 years (range 25–79 years). Wide local excision was performed for 11 patients and 9 patients were treated combined with chemotherapy. The 5-year disease-specific survival (DSS) rate was 53.9%. The 5-year DSS rates for patients treated with adjuvant/neoadjuvant chemotherapy or not were 66.7% or 25%, respectively (p = 0.0215). Furthermore, the 5-year DSS rates for patients treated with adjuvant/neoadjuvant chemotherapy consisting of doxorubicin and ifosfamide and those treated with other regimens were 100% or 40%, respectively (p = 0.0327).
Conclusion
The present study demonstrated that adjuvant/neoadjuvant chemotherapy, especially consisting of doxorubicin and ifosfamide, was potentially efficacious for ESOS. Further prospective study using this multimodality treatment approach to patients with ESOS should be strongly warranted.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Allan CJ, Soule EH (1971) Osteogenic sarcoma of the somatic soft tissues: clinicopathologic study of 26 cases and review of literature. Cancer 27:1121–1133
Chung EB, Enzinger FM (1978) Extraskeletal osteosarcoma. Cancer 1987(60):1132–1142
Rao U, Cheng A, Didolkar MS (1978) Extraosseous osteogenic sarcoma: clinicopathological study of eight cases and review of literature. Cancer 41:1488–1496
Sordillo PP, Hajdu SI, Magill GB et al (1983) Extraosseous osteogenic sarcoma: a review of 48 patients. Cancer 51:727–734
Bane BL, Evans HL, Ro JY et al (1990) Extraskeletal osteosarcoma: a clinicopathologic review of 26 cases. Cancer 65:2762–2770
Ahmad SA, Patel SR, Ballo MT et al (2002) Extraosseous osteosarcoma: response to treatment and long-term outcome. J Clin Oncol 20:521–527
Goldstein-Jackson SY, Gosheger G, Delling G et al (2005) Cooperative Osteosarcoma Study Group COSS. Extraskeletal osteosarcoma has a favourable prognosis when treated like conventional osteosarcoma. J Cancer Res Clin Oncol 131:520–526
Lee JS, Fetsch JF, Wasdhal DA et al (1995) A review of 40 patients with extraskeletal osteosarcoma. Cancer 76:2253–2259
Lee S, Lee MR, Lee SJ et al (2010) Extraosseous osteosarcoma: single institutional experience in Korea. Asia Pac J Clin Oncol 6:126–129
Patel SR, Benjamin RS (1995) Primary extraskeletal osteosarcoma: experience with chemotherapy. J Natl Cancer Inst 87:1331–1333
Choi LE, Healey JH, Kuk D et al (2014) Analysis of outcomes in extraskeletal osteosarcoma: a review of fifty-three cases. J Bone Jt Surg Am 96(1):e2(1−8)
Sio TT, Vu CC, Sohawon S et al (2016) Extraskeletal osteosarcoma: an international rare cancer network study. Am J Clin Oncol 39:32–36
Torigoe T, Yazawa Y, Takagi T et al (2007) Extraskeletal osteosarcoma in Japan: multiinstitutional study of 20 patients from the Japanese Musculoskeletal Oncology Group. J Orthop Sci 12:424–429
Fan Z, Patel S, Lewis VO et al (2015) Should high-grade extraosseous osteosarcoma be treated with multimodality therapy like other soft tissue sarcomas? Clin Orthop Relat Res 473:3604–3611
Longhi A, Bielack SS, Grimer R et al (2017) Extraskeletal osteosarcoma: a European Musculoskeletal Oncology Society study on 266 patients. Eur J Cancer 74:9–16
Nystrom LM, Reimer NB, Reith JD et al (2016) The treatment and outcomes of extraskeletal osteosarcoma: institutional experience and review of the literature. Iowa Orthop J 36:98–103
Paludo J, Fritchie K, Haddox CL et al (2018) Extraskeletal osteosarcoma: outcomes and the role of chemotherapy. Am J Clin Oncol 41(9):832–837
Acknowledgements
We thank all the participants who treated ESOS patients of current study in Osaka University Orthopaedic Oncology Group.
Funding
We have no funding.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Wakamatsu, T., Kakunaga, S., Takenaka, S. et al. Prognostic implication of adjuvant/neoadjuvant chemotherapy consisting of doxorubicin and ifosfamide in patients with extraskeletal osteosarcoma. Int J Clin Oncol 24, 1311–1319 (2019). https://doi.org/10.1007/s10147-019-01475-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-019-01475-1